Since the discovery of the association between the c.1521_1523delCTT mutation of the cystic fibrosis transmembrane conductance regulator (CFTR) gene with cystic fibrosis (CF) development in 1989, technologies for screening CFTR gene mutations such as high‐throughput sequencing (HTS), also known as next‐generation sequencing, have assumed a key role in diagnosis and precision medicine based on genotype‐specific small molecule therapies.1 Here, CFTR is linked to cystic fibrosis.